获得诱导性肝细胞样细胞的策略研究

The Strategy for Acquiring Induced Hepatocyte-Like Cells

原位肝移植是目前治疗终末期肝衰竭等疾病最有效的办法,但供体来源少、手术费用昂贵等问题使得每年能够接受肝移植的病人非常少。肝细胞移植弥补了整个肝脏移植的不足,成为治疗肝病的最佳方案,但实验证明不论是在二维还是三维培养体系下原代肝细胞均无法在体外大量扩增,这极大地限制了其在临床上的广泛应用。多能干细胞以及肝干细胞可以在体外大量扩增且具有肝向分化潜能,因此近年来研究者致力于研究如何获得大量的具备成熟肝细胞功能的肝细胞样细胞。该文概述了目前获得诱导性肝细胞样细胞的策略及其潜在临床应用价值,以期为今后临床上终末期肝病肝细胞治疗的应用提供有效思路。

Orthotopic liver transplantation is the most effective method for the treatment of end-stage liver diseases including liver failure,but only a few patients achieve liver transplantation because of the limited organ donor and expensive surgery.Hepatocyte transplantation has been considered as the best alternative to orthotopic liver transplantation in the treatment of liver diseases.However,evidences have reported that primary hepatocytes can not be massively expanded in vitro under either 2D or 3D culture system,greatly limiting its clinical application.Pluripotent stem cells or liver stem cells have the advantage of in vitro expansion for several passages and the potential capacity of differentiation.In recent years,researchers focused on how to acquire a large number of mature hepatocyte-like cells.This review summarized the current strategies and potential clinical value for acquiring induced hepatocyte-like cells,for developing clinical approaches of cell therapy in end-stage liver diseases.